Anxiety and work impairment

Anxiety's workplace cost is usually broken into two parts. Absenteeism is easier to see: missed shifts, sick days, and unplanned leave. Presenteeism is harder to see: hours at work with reduced concentration, slower task completion, more errors, and lower creative output. Analyses using instruments like the Work Productivity and Activity Impairment questionnaire consistently find that presenteeism accounts for more of the total workplace cost of anxiety and depression than absenteeism does.

Greenberg and colleagues' 1999 paper in the Journal of Clinical Psychiatry compiled the first comprehensive US estimate of the economic burden of anxiety disorders, at about $42 billion per year (1990 dollars), roughly a third of it from workplace productivity. The estimate has been updated for depression (Greenberg's 2015 and 2021 depression-specific updates), but anxiety-specific US updates are less common. International reviews, including Konnopka and König's 2020 review in PharmacoEconomics, reach comparable conclusions about the size and distribution of the anxiety-disorder cost.

Social Security Disability Insurance and Supplemental Security Income data show that mental health conditions have grown as a share of new disability awards over the past two decades, with mood and anxiety disorders together representing a substantial share. The disability figures are downstream of clinical severity and of workplace accommodations, and different countries handle disability differently, so international comparisons need care.

Randomized trials of anxiety treatment consistently find improvements in work-related functioning alongside symptom improvement, with effect sizes tracking those of symptom reduction. The CALM trial (Roy-Byrne et al., 2010), which tested collaborative care for anxiety in primary care, reported improvements in work functioning as well as symptom scores. Whether treatment scales up to reduce population-level disability claims is harder to establish and depends on access as much as on effectiveness.

Anxiety disorders carry a measurable cost at work, and the cost shows up in two forms. The first is absenteeism, missed days of work. The second is presenteeism, reduced productivity while present, which is harder to see but, in several analyses, it's the larger share of the total cost. Kessler and colleagues' work with the National Comorbidity Survey Replication data quantified anxiety-related lost work days and days of impaired function.

Burden-of-illness research has placed the economic cost of anxiety disorders in the United States in the tens of billions of dollars a year, with lost workplace productivity a major component. The foundational US burden estimate, by Greenberg and colleagues in the Journal of Clinical Psychiatry (1999), placed the annual cost at about $42 billion in 1990 dollars, and subsequent updates have not reversed the direction. Konnopka and colleagues' international review in 2020 reached comparable conclusions on the workplace-productivity share.

Anxiety also intersects with disability. Anxiety disorders are among the conditions cited in disability claims, often alongside depression, and the share of Social Security Disability Insurance awards involving a mental health condition has grown over time. The functional reach of anxiety doesn't stop at the clinic; it extends into earnings, employment stability, and the broader economy.

Burden-of-illness estimates depend heavily on the costing method and the year. Treat the 'tens of billions' framing as an order-of-magnitude statement, not a precise figure.

Presenteeism is estimated indirectly, usually through self-report scales like the Work Productivity and Activity Impairment questionnaire, and so carries measurement uncertainty.